Trade Mark Journal No.2021/053 31 December 2021

WO0000001631368 (5,42)

Office of origin: United States of America

Date of International Registration:4 November 2021
Date of designation in the UK: 4 November 2021
Image for mark 1631368

The mark consists of the text "AsherBio" in stylized font. The bottom half of the "A" appears as a semi-circle.

International priority date claimed: 6 May 2021 (United States of America) (90694701)
Class 5
Pharmaceutical products for the treatment of cancer; pharmaceutical preparations and substances for the treatment of viral, oncological, and immune system related diseases and disorders; medical preparations for the treatment of viral, oncological, and immune system related diseases and disorders.
Class 42
Medical research; pharmaceutical research services; pharmaceutical research and development; scientific research for medical purposes in the fields of cancerous diseases, immunotherapy, autoimmune diseases and disorders, and infectious diseases; development of pharmaceutical preparations and medicines; research and development of pharmaceuticals for the treatment of cancer, immunological diseases and disorders, and infectious diseases; research and development of immunotherapies for the treatment of cancer; providing medical and scientific research information in the field of pharmaceuticals and clinical trials.

Asher Biotherapeutics, Inc.

Representative: Joyce Liou Morrison & Foerster LLP, 425 Market Street, San Francisco CA 94105, UNITED STATES OF AMERICA